Tissue Resources and Molecular Pathology

组织资源和分子病理学

• 批准号: 8747070
• 负责人: IGNACIO I. WISTUBA
• 金额: $ 23.99万
• 依托单位: UT SOUTHWESTERN MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-09-30 至 2019-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8747070
• 关键词: B-Lymphocytes; Basic Science; Belief; Bioinformatics; Biological Assay; Biometry; Blood Banks; Blood Cells; Blood specimen; Cancer Center; Cancer cell line; Cataloging; Catalogs; Cell Line; Cells; Clinical; Clinical Data; Clinical Research; Clinical Trials; Collaborations; Collection; Colorado; Complement; DNA; Data; Development; Drug or chemical Tissue Distribution; Epithelial Cells; Funding; Grant; Guidelines; Institution; Investigation; Lung; Malignant - descriptor; Malignant neoplasm of lung; Medicine; Methodology; Molecular; Mutation; Non-Malignant; Non-Small-Cell Lung Carcinoma; Outcome; Paraffin; Pathogenesis; Pathologic; Pathology; Patients; Peer Review; Play; Positioning Attribute; Process; Proteins; Publications; RNA; Reagent; Research; Research Activity; Research Personnel; Research Project Grants; Resources; Role; Sampling; Services; Site; Specimen; Surgical Pathology; Testing; Tissue Banking; Tissue Banks; Tissue Microarray; Tissue Procurements; Tissues; Translational Research; Tumor Cell Line; United States National Institutes of Health; Xenograft procedure; Yale Cancer Center; base; biobank; cell bank; clinical application; data sharing; genome-wide; high standard; innovation; molecular pathology; novel; programs; success; tissue processing; tissue resource; tumor

The Pathology and Tissue Resources Core will provide routine and innovative tissue resources and materials essential for achieving the aims of the SPORE projects. Routine materials include tumors and non-malignant lung specimens and tumor cell lines. Over 3,000 tumors and 300 lung cancer cell lines have been banked, and over 50,000 aliqouts of tumor or cell line pellets, RNA or DNA or paraffin sections have been distributed to investigators. Our Aim 1 is to collect, process, store, catalog and distribute tissues, cell lines and blood specimens, both malignant and nonmalignant, and relevant clinico-pathologic and molecular data, as requested by the various component projects of the SPORE program. Aim 2 is to develop and utilize innovative and routine tissue and cell line resources that will aid in the successful completion of the SPORE program aims. These include development of new tumor cell line resources to complement recent genome wide mutation data on lung cancer oncogenotypes. Aim 3 is to perform and interpret tissue-based molecular methodologies in close collaboration with the component projects of the SPORE program to satisfy their approved aims. This will involve developing molecular assays that eventually can be deployed as CLIA certified lab tests to facilitate the planned translational science clinical trials in most of the SPORE projects. This Core will play a crucial role on promoting collaboration among our own SPORE investigators, investigators at other Lung Cancer SPORE sites, and investigators at our own and other institutions including other peer-reviewed projects funded by NCI/NIH and other agencies. All of our SPORE projects will utilize Core B materials and services. Heavy utilization of our routine and innovative materials, and close interactions with the SPORE investigators will greatly aid the successful completion of the aims of our SPORE proposal.

病理和组织资源核心将为实现孢子项目的目标提供常规和创新的组织资源和材料。常规材料包括肿瘤和非恶性肺标本和肿瘤细胞系。已将超过3,000个肿瘤和300个肺癌细胞系进行了库，并将超过50,000个肿瘤或细胞系颗粒，RNA或DNA或石蜡切片分布给研究人员。我们的目标1是按照孢子计划的各个组成项目的要求，收集，加工，商店，目录和分布组织，细胞系和血液标本以及相关的临床病理学和分子数据。目标2是开发和利用创新的和常规的组织和细胞系资源，这将有助于成功完成孢子计划的目标。其中包括开发新的肿瘤细胞系资源，以补充有关肺癌癌基因型的最新基因组突变数据。目标3是在与孢子计划的组成项目密切合作中执行和解释基于组织的分子方法，以满足其认可的目标。这将涉及开发分子测定法，最终可以将其作为CLIA认证的实验室测试部署，以促进大多数孢子项目中计划的转化科学临床试验。该核心将在促进我们自己的孢子调查人员，其他肺癌孢子部位的研究人员以及我们自己和其他机构的研究人员之间的合作方面发挥至关重要的作用，包括NCI/NIH和其他机构资助的其他同行评审项目。我们所有的孢子项目都将利用核心B材料和服务。大量利用我们的日常和创新材料，以及与孢子调查人员进行密切相互作用将极大地帮助成功完成我们的孢子提案的目标。